Literature DB >> 2879870

Lymphokine-activated killer (LAK) cells. II. Delineation of distinct murine LAK-precursor subpopulations.

Z K Ballas, W Rasmussen, J K van Otegham.   

Abstract

Lymphokine-activated killer (LAK) cells can lyse a number of tumor target cells regardless of whether the tumors are natural killer (NK) sensitive or resistant. LAK can also lyse autologous lymphoblasts that have been modified with 2,4,6-trinitrobenzene sulfonic acid (TNBS). In this study, we examined the surface markers of murine LAK precursors. It was found that depletion of Thy 1- or Lyt 2-bearing precursor cells abolished the ability of spleen cells to generate LAK against TNBS-self, but had no effect on the generation of LAK against tumor cells. Depletion of asialo-GM1 (AGM1)-bearing precursors abolished the generation of LAK against all target cells tested. Normal spleen cells were fractionated on a Percoll density gradient and two fractions were examined: fraction (Fxn) 3, which is enriched for NK activity but depleted of the ability to generate cytotoxic T lymphocytes (CTL), and Fxn 5, which had no NK activity but was enriched for the ability to generate CTL. Both fractions were capable of generating LAK, although Fxn 5 required a relatively larger amount of interleukin 2 (IL 2). Upon examination of the surface markers of LAK precursors in these fractions it was found that the precursors in Fxn 3 giving rise to LAK against tumors were Thy-1-, Lyt-2-, AGM1+, whereas the precursors in Fxn 5 were Thy-1+, Lyt-2+, AGM1+. The precursors generating LAK against TNBS-self were Thy-1+, Lyt-2+, AGM1+ in both fractions. The time kinetics of LAK generation in both fractions were different, with Fxn 3 showing much earlier kinetics. These data delineate at least two different LAK precursors defined by their buoyant density, by their surface markers, and by their susceptible target cells. These data also may resolve the confusion in the literature regarding the phenotype of LAK precursors.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2879870

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  12 in total

1.  Effect of culture media on lymphokine-activated killer effector phenotype and lytic capacity.

Authors:  D M Finkelstein; R G Miller
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

2.  Antitumor effects of interleukin-2 and mismatched double-stranded RNA, individually and in combination, against a human malignant melanoma xenograft.

Authors:  H R Hubbell; H E Vargas; K L Tsujimoto; G D Gibson; E C Pequignot; R D Bigler; W A Carter; D R Strayer
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

3.  Augmentation of murine lymphokine-activated killer cell cytotoxicity by beta-cyclodextrin-benzaldehyde.

Authors:  Y Kuroki; H Ochiai; M Kurokawa; S Niwayama; C Kishimoto; K Tazawa; M Fujimaki
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

4.  Combined activation of murine lymphocytes with staphylococcal enterotoxin and interleukin-2 results in additive cytotoxic activity.

Authors:  H Belfrage; P Bhiladvala; G Hedlund; M Dohlsten; T Kalland
Journal:  Cancer Immunol Immunother       Date:  1994-04       Impact factor: 6.968

Review 5.  Interleukin-2 in cancer treatment: disappointing or (still) promising? A review.

Authors:  R A Maas; H F Dullens; W Den Otter
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

Review 6.  Modulation of NK cell activity by CpG oligodeoxynucleotides.

Authors:  Zuhair K Ballas
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

7.  Mouse tumors are heterogeneous in their susceptibility to syngeneic lymphokine-activated killer cells and delineate functional subsets in such effectors.

Authors:  M Sensi; L Grazioli; M Rodolfo; G Parmiani
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

8.  Toxicity and therapeutic efficacy of high-dose interleukin 2. In vivo infusion of antibody to NK-1.1 attenuates toxicity without compromising efficacy against murine leukemia.

Authors:  D J Peace; M A Cheever
Journal:  J Exp Med       Date:  1989-01-01       Impact factor: 14.307

9.  Human lymphokine-activated killer cells are cytotoxic against cells infected with Toxoplasma gondii.

Authors:  C S Subauste; L Dawson; J S Remington
Journal:  J Exp Med       Date:  1992-12-01       Impact factor: 14.307

10.  T cell receptor-independent cell-mediated cytotoxicity by nude mouse lymphokine-activated killer cells.

Authors:  T Nishimura; Y Togashi; N Wakamiya; Y Hashimoto; H Yagita; K Okumura; S Habu
Journal:  Jpn J Cancer Res       Date:  1991-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.